4-amino-2,6-dichlorophenol, also known as 2,6-dichloro-4-aminophenol, is a chemical compound that has been studied for its potential use in various applications. It is a white to light brown solid, and its synthesis involves the reaction of 2,6-dichloro-4-nitrophenol with a reducing agent such as iron or tin. The compound exhibits antimicrobial activity against a range of bacteria and fungi, and it has also been investigated as a potential drug for the treatment of diseases such as cancer and Alzheimer's disease. Its biological activity is attributed to its ability to act as an inhibitor of enzymes involved in cell growth and proliferation. Furthermore, 4-amino-2,6-dichlorophenol is a valuable intermediate in the synthesis of various other chemicals, including dyes, pharmaceuticals, and pesticides. Research into this compound is ongoing to explore its potential applications and to gain a deeper understanding of its biological effects.'
ID Source | ID |
---|---|
PubMed CID | 80037 |
CHEMBL ID | 1454590 |
SCHEMBL ID | 93999 |
MeSH ID | M0233352 |
Synonym |
---|
4-amino-2,6-dichloro-phenol |
BB 0246798 |
i0l4csx5n0 , |
unii-i0l4csx5n0 |
phenol, 4-amino-2,6-dichloro- |
nsc 156835 |
einecs 227-671-4 |
2,6-dichloro-p-aminophenol |
3,5-dichloro-4-hydroxyaniline |
5930-28-9 |
2,6-dichloro-4-aminophenol |
nsc156835 |
4-amino-2,6-dichlorophenol |
nsc-156835 |
inchi=1/c6h5cl2no/c7-4-1-3(9)2-5(8)6(4)10/h1-2,10h,9h |
4-amino-2,6-dichlorophenol, 98% |
NCGC00164211-01 |
A0878 |
A832251 |
AKOS003632277 |
dtxcid1020720 |
tox21_301640 |
dtxsid3040720 , |
cas-5930-28-9 |
NCGC00255453-01 |
FT-0617453 |
AM20040801 |
4-hydroxy-3,5-dichloroaniline |
SCHEMBL93999 |
4-amino-2,6-dichloro phenol |
2,6-dichloro-4-amino phenol |
J-610057 |
W-105332 |
CHEMBL1454590 |
AC-26233 |
mfcd00007875 |
SY046976 |
F1196-0334 |
AS-10946 |
EN300-123163 |
STL196591 |
Q27280208 |
CS-W017353 |
Excerpt | Reference | Relevance |
---|---|---|
" The toxic process might also be mediated by glutathione (GSH) conjugates of ADCP, as suggested for the mechanism of 4-aminophenol nephrotoxicity." | ( 4-Amino-2,6-dichlorophenol nephrotoxicity in the Fischer 344 rat: protection by ascorbic acid, AT-125, and aminooxyacetic acid. Anestis, DK; Ball, JG; Brown, PI; Hong, SK; Rankin, GO; Valentovic, MA, 1997) | 1.74 |
" The mechanism of chloroaniline nephrotoxicity may occur via more than one mechanism, but aminochlorophenol metabolites appear to contribute to the adverse in vivo effects." | ( 4-Amino-2-chlorophenol: Comparative in vitro nephrotoxicity and mechanisms of bioactivation. Anestis, DK; Ferguson, T; Preston, D; Racine, C; Rankin, GO; Sweeney, A, 2014) | 0.4 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
acetylcholinesterase | Homo sapiens (human) | Potency | 68.0110 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347397 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 64.8601 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 24.4363 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 46.4688 | 0.0002 | 21.2231 | 8,912.5098 | AID588516; AID743035; AID743036; AID743063 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 19.3312 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 55.1932 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 30.8956 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 41.1375 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 42.9005 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588544; AID588546 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 49.8047 | 0.3758 | 27.4851 | 61.6524 | AID588526; AID743220 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 68.5896 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 31.7617 | 0.0002 | 29.3054 | 16,493.5996 | AID588513; AID588514; AID743069; AID743075; AID743078 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 25.6958 | 0.0010 | 24.5048 | 61.6448 | AID588534; AID588535; AID743215 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 39.2004 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID743094; AID743191 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 61.1373 | 0.0237 | 23.2282 | 63.5986 | AID588541; AID743223 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 54.8442 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 61.6448 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 56.0157 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 100.7150 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 85.2802 | 0.0100 | 39.5371 | 1,122.0200 | AID1479; AID588547 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 61.5361 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 54.4827 | 0.0376 | 17.0823 | 61.1927 | AID1259364 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 54.9410 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 28.8683 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636; AID743202; AID743219 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 74.1159 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (42.86) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.83) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |